無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脳腫瘍の治療:世界市場 2023年

Brain Tumor Therapeutics: Global Markets to 2023

発行 BCC Research 商品コード 762927
出版日 ページ情報 英文 161 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.39円で換算しております。
Back to Top
脳腫瘍の治療:世界市場 2023年 Brain Tumor Therapeutics: Global Markets to 2023
出版日: 2018年12月27日 ページ情報: 英文 161 Pages
概要

世界における脳腫瘍治療薬の市場規模は、2018年の11億米ドルから、2023年までに20億米ドルへ拡大すると予測され、2018年から2023年にかけては12.9%のCAGR (年間複合成長率) が見込まれています。

当レポートでは、世界における脳腫瘍治療市場について調査し、世界市場の概要、国別のデータと分析、主な市場成長の促進要因・抑制要因、地域的なダイナミクス、および主要企業のプロファイルなどを提供しています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 疾患の背景・概要

  • イントロダクション
  • 疾患の背景
  • 脳腫瘍の診断
  • 脳腫瘍の再発・管理
  • 治療法

第4章 市場ダイナミクス

  • イントロダクション
  • 市場成長の促進要因
  • 市場成長の抑制要因
  • 現在の市場動向

第5章 市場分析:治療法別

  • イントロダクション
  • 化学療法
  • 標的療法
  • 免疫療法

第6章 市場分析:患者年齢別

  • イントロダクション
  • 概要
  • 治療の選択肢
  • 市場概要
  • 市場規模・予測

第7章 市場分析:エンドユーザー別

第8章 市場分析:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • その他

第9章 新興技術・将来の動向

  • イントロダクション
  • 癌ワクチン
  • ナノメディシン
  • 幹細胞療法
  • 光線力学療法
  • 集束超音波療法
  • ラジオミクス & パソミクス
  • CRISPR
  • 人工知能 (AI)
  • ゲノミクス・オーダーメイド医療における進歩

第10章 脳腫瘍治療薬の臨床研究

  • イントロダクション
  • 創薬プロセス
  • 研究イニシアチブ
  • 治験・実験的治療

第11章 特許レビュー

第12章 競合情勢・市場戦略

  • イントロダクション
  • 主要企業・市場シェア分析
  • 主要企業が採用する市場戦略
  • 新規開発
  • ポーターのファイブフォース分析

第13章 規制・医療費償還の状況

  • イントロダクション
  • 創薬の規制
  • 医療費償還の状況

第14章 企業プロファイル

付録:頭字語

BBC Researchについて

図表

List of Tables

  • Summary Table: Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2023
    • Table 1: WHO Grading of Brain Tumors
    • Table 2: WHO Grading of Select Brain Tumors
    • Table 3: Survival Rates for Common Adult Brain and Spinal Cord Tumors, 2017
    • Table 4: Brain Structures and Functions
    • Table 5: WHO Classification of Brain Tumors, 2016
    • Table 6: Karnofsky Performance Scale
    • Table 7: Specific Types of Brain Tumor Metastasis
    • Table 8: Parts of the Brain Related to Major Cognitive Functions
    • Table 9: Timeline of Significant Developments in Radiotherapy, 1898-2006
    • Table 10: Rare/Orphan Drug Criteria: Selected Regulatory Organizations
    • Table 11: Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2023
    • Table 12: FDA-Approved Drugs Used in Brain Tumor Chemotherapy
    • Table 13: Dosage and Administration of Temozolomide for Brain Tumors
    • Table 14: Current Brain Tumor Clinical Trials: Temozolomide
    • Table 15: Current Brain Tumor Clinical Trials involving Lomustine
    • Table 16: Current Brain Tumor Clinical Trials involving Carmustine
    • Table 17: PCV Regimen: Brain Tumor Chemotherapy
    • Table 18: Global Market for Brain Tumor Chemotherapy, by Region, Through 2023
    • Table 19: FDA Approved Targeted Therapeutic Agents for Brain Tumors
    • Table 20: Monoclonal Antibodies
    • Table 21: Small Molecule Monoclonal Antibodies
    • Table 22: Current Brain Tumor Clinical Trials involving Bevacizumab
    • Table 23: Current Brain Tumor Clinical Trials involving Everolimus
    • Table 24: Global Market for Brain Tumor Targeted Therapy, by Region, Through 2023
    • Table 25: Current Brain Tumor Clinical Trials: Immunotherapy
    • Table 26: Global Market for Brain Tumor Therapeutics, by Patient Age, Through 2023
    • Table 27: Hereditary Factors: Pediatric Brain Tumors
    • Table 28: Global Market for Adult Brain Tumor Therapeutics, by Region, Through 2023
    • Table 29: Global Market for Pediatric Brain Tumor Therapeutics, by Region, Through 2023
    • Table 30: Global Market for Brain Tumor Therapeutics Market, by End User, Through 2023
    • Table 31: Global Market for Brain Tumor Therapeutics in Hospitals, by Region, Through 2023
    • Table 32: Global Market for Brain Tumor Therapeutics in Research Institutes, by Region, Through 2023
    • Table 33: Global Market for Brain Tumor Therapeutics in Universities, by Region, Through 2023
    • Table 34: Global Market for Brain Tumor Therapeutics , by Region, Through 2023
    • Table 35: North American Market for Brain Tumor Therapeutics, by Country, Through 2023
    • Table 36: European Market for Brain Tumor Therapeutics, by Country, Through 2023
    • Table 37: Asia-Pacific Market for Brain Tumor Therapeutics, by Country, Through 2023
    • Table 38: Drug Development
    • Table 39: Selected Current Phase I Brain Tumor Clinical Trials
    • Table 40: Selected Current Phase II Brain Tumor Clinical Trials
    • Table 41: Selected Current Phase III Brain Tumor Clinical Trials
    • Table 42: Patent Review of Novel Compounds and Drug Delivery in Brain Tumors, February 2017 to August 2018
    • Table 43: Patent Review of Therapeutic Agents for Brain Tumors, January 2017 to August 2018
    • Table 44: Patent Review of Combination Therapies in Brain Tumors, September 2017 to September 2018
    • Table 45: Patent Review of Immunotherapies for Brain Tumors, December 2016 to July 2018
    • Table 46: Patent Review of Diagnosis and Biomarkers in Brain Tumors, January 2017 to September 2018
    • Table 47: Ongoing Clinical Trials and Product Pipeline Involving Major Players in Brain Tumor Therapeutics
    • Table 48: Current Orphan Drug Designations for Brain Tumors
    • Table 49: Bristol-Myers Squibb: Revenue 2016 and 2017
    • Table 50: Bristol-Myers Squibb: Brain Tumor Pharmaceuticals
    • Table 51: Opdivo Approvals, 2017
    • Table 52: F. Hofmann-La Roche: Revenue 2016 and 2017
    • Table 53: F. Hofmann-La Roche: Brain Tumor Pharmaceutical Drugs
    • Table 54: Merck & Co., Inc.: Revenue 2016 and 2017
    • Table 55: Merck & Co., Inc.: Brain Tumor Pharmaceutical Drugs
    • Table 56: NextSource Biotechnology LLC: Brain Tumor Therapeutics
    • Table 57: Novartis: Revenue 2016 and 2017
    • Table 58: Novartis: Brain Tumor Pharmaceuticals
    • Table 59: Important Acronyms Related to Brain Tumor Therapeutics Used in This Report

List of Figures

  • Summary Figure: Global Market for Brain Tumor Therapeutics, by Therapy Type, 2017-2023
    • Figure 1: Percentage Share of Global Cancer Incidence, by Type, 2018
    • Figure 2: Percentage Share of Global Cancer Incidence, by Region, 2018
    • Figure 3: Hallmarks of Cancer
    • Figure 4: Five Year Relative Survival at Diagnosis, by Stage, 2014-2018
    • Figure 5: Goals of Surgical Treatment for Brain Tumors
    • Figure 6: Global Expenditures on Oncology Drugs, by Country/Region, 2013-2017
    • Figure 7: Projected Global Expenditures on Oncology Drugs, by Country/Region, 2020
    • Figure 8: Global Market for Brain Tumor Therapeutics, by Therapy Type, 2017-2023
    • Figure 9: Global Market for Brain Tumor Chemotherapy, by Region, 2017-2023
    • Figure 10: Targeted Therapy Types
    • Figure 11: Global Market for Brain Tumor Targeted Therapy, by Region, 2017-2023
    • Figure 12: Global Market for Brain Tumor Therapeutics, by Patient Age, 2017-2023
    • Figure 13: Percentage Share of Common Adult Brain Tumor Incidence, by Type, 2017
    • Figure 14: Percentage Share of Common Pediatric Brain Tumor Incidence, 2017
    • Figure 15: Differences: Adult and Pediatric Brain Tumors
    • Figure 16: Etiology: Pediatric Brain Tumors
    • Figure 17: Global Market for Adult Brain Tumor Therapeutics, by Region, 2017-2023
    • Figure 18: Global Market for Pediatric Brain Tumor Therapeutics, by Region, 2017-2023
    • Figure 19: Global Market for Brain Tumor Therapeutics in Hospitals, by Region, 2017-2023
    • Figure 20: Global Market for Brain Tumor Therapeutics in Research Institutes, by Region, 2017-2023
    • Figure 21: Global Market for Brain Tumor Therapeutics in Universities, by Region, 2017-2023
    • Figure 22: Global Incidence of Brain Tumors, 2018-2040
    • Figure 23: Global Market for Brain Tumor Therapeutics Market, by Region, 2017-2023
    • Figure 24: North American Incidence of Brain Tumors, 2018-2040
    • Figure 25: North American Market for Brain Tumor Therapeutics, 2017-2023
    • Figure 26: North American Market for Brain Tumor Therapeutics, by Country, 2017-2023
    • Figure 27: European Incidence of Brain Tumors, 2018-2040
    • Figure 28: European Market for Brain Tumor Therapeutics, 2017-2023
    • Figure 29: European Market for Brain Tumor Therapeutics, by Country, 2017-2023
    • Figure 30: Asia-Pacific Incidence of Brain Tumors, 2018-2040
    • Figure 31: Asia-Pacific Market for Brain Tumor Therapeutics, 2017-2023
    • Figure 32: Asia-Pacific Market for Brain Tumor Therapeutics, by Country, 2017-2023
    • Figure 33: ROW Market for Brain Tumor Therapeutics, 2017-2023
    • Figure 34: Pharmaceutical Drug Development
    • Figure 35: Current Clinical Trials, by Phase, 2018
    • Figure 36: Major Market Players Share in Brain Tumor Therapeutics Market, 2017
    • Figure 37: NIH Funding for Brain Cancer R&D, 2016-2018
    • Figure 38: R&D Expenditure of Top 3 Players in Brain Tumor Therapeutics, 2017
    • Figure 39: Bargaining Power of Buyers in the Brain Tumor Therapeutics Industry
    • Figure 40: Bargaining Power of Suppliers in the Brain Tumor Therapeutics Industry
    • Figure 41: Threat from New Entrants in the Brain Tumor Therapeutics Industry
    • Figure 42: Threat from Substitutes in the Brain Tumor Therapeutics Industry
    • Figure 43: Market Competition in the Brain Tumor Therapeutics Industry
    • Figure 44: Pharmaceutical Regulatory Pathways in the U.S and Europe
    • Figure 45: Bristol-Myers Squibb: Net Sales, by Region/Country, 2017
    • Figure 46: Bristol-Myers Squibb: R&D Expenditure, 2016 and 2017
    • Figure 47: Roche Top 5 Pharmaceutical Drugs, by Sales Revenue, 2017
    • Figure 48: Avastin: Sales Revenue, 2016 and 2017
    • Figure 49: F. Hofmann-La Roche: Revenue Share, by Business Segment, 2017
    • Figure 50: F. Hofmann-La Roche: Revenue, by Region, 2015-2017
    • Figure 51: Roche Product Pipeline, by Disease Area, 2017
    • Figure 52: Novartis: Net Sales, by Division, 2017
    • Figure 53: Novartis: Net Sales, by Region, 2017
目次
Product Code: PHM208A

Report Highlights:

The global market for brain tumor therapeutics should grow from $1.1 billion in 2018 to reach $2.0 billion by 2023 at a compound annual growth rate (CAGR) of 12.9% for the period of 2018-2023.

Chemotherapy segment of brain tumor therapeutics market should grow from $771.3 million in 2018 to reach $1.3 billion by 2023 at a CAGR of 11.1% for the period of 2018-2023.

Targeted therapy segment of brain tumor therapeutics market should grow from $297.2 million in 2018 to reach $652.8 million by 2023 at a CAGR of 17.0% for the period of 2018-2023.

Report Scope:

This report provides an overview of the current and future global market potential for brain tumor therapeutics. It provides a detailed analysis and information about conventional treatment options, ongoing market trends and the future direction of the market with respect to brain tumor therapy.

Inclusions

  • The report covers a detailed background of the disease state, along with epidemiological and demographic data, market segmentation by therapy (chemotherapy and targeted therapy), age group of patients (adult and pediatric brain tumors), end users (hospitals, cancer research institutes and medical universities) and a detailed regional market analysis including North America, Europe, Asia-Pacific and the rest of the world.
  • The report provides information on newer treatment opportunities and cutting-edge research on therapeutics for brain tumors. It covers various types of treatment used in the field of neuro-oncology: surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy.
  • A detailed analysis of agents used in the market for chemotherapy, immunotherapy and targeted therapy, as well as a pipeline analysis of newer molecules and therapeutics is covered in the report.
  • A comprehensive analysis of market dynamics in the industry and current market trends are described in the report, along with the competitive landscape and discussion about key market players in the field of brain tumor therapeutics, where market strategies of these players are studied and described. The report includes a patent analysis of brain tumor therapeutics.
  • The report concludes with company profiles of key players in the development and commercialization of brain tumor therapeutics.
  • A separate chapter on emerging trends and breakthrough technologies in the field of neuro-oncology has been included in this report.

Exclusions

Excluded from this report are the market size for equipment used in radiotherapy, surgical equipment and supplies and market size for drugs used for the symptomatic management of cancer (anti-epileptics, anti-emetics and hormonal medications). This report also excludes market size for immunotherapy. This is not a proven treatment for brain tumors and is currently being developed in research and clinical trials.

Market values are provided for 2017 as base year, 2018 and forecast through 2023.Estimated values are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

  • 20 data tables and 40 additional tables
  • Comprehensive overview of the global market for brain tumor therapeutics within the pharmaceutical industry
  • Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Country specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa
  • Impact analysis of major drivers and restraints, and regional dynamics of the global brain tumor therapeutics markets and current trends within the industry
  • Company profiles of prominent players in the market, including Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Novartis International AG

Table of Contents

Chapter 1: Introduction

  • Scope of Report
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Information Sources and Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

  • Key Findings

Chapter 3: Disease Background and Overview

  • Introduction
    • What is Cancer?
    • Cancer Drivers
    • Cancer Staging
  • Disease Background
    • Brain Tumor Statistics
    • Human Brain Function
    • Causes of Tumor Development
    • Mechanism of Tumorigenesis
    • Types and Classification of Brain Tumors
  • Diagnosis of Brain Tumors
    • Magnetic Resonance Imaging (MRI)
    • Magnetic Resonance Spectroscopy (MRS)
    • Tissue Sampling/Biopsy/Surgical Removal of Tumor
    • Computed Tomography (CT)
    • Positron Emission Tomography (PET) or PET-CT Scan
    • Cerebral Arteriogram
    • Lumbar Puncture or Spinal Tap
    • Myelogram
    • Molecular Testing
    • Neurological, Vision and Hearing Tests
    • Neurocognitive Assessment
    • Electroencephalography (EEG)
    • Evoked Potentials
  • Recurrence of Brain Tumors and Management
    • Brain Tumor Metastases and Management
    • Cognitive Challenges
    • Pain Management
  • Treatment Modalities
    • Surgery
    • Neurosurgery
    • Emerging Treatments in Neurosurgery
    • Radiotherapy
    • New and Emerging Treatments in Neuro-radiotherapy
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy

Chapter 4: Market Dynamics

  • Introduction
  • Market Drivers
    • Increasing Global Incidence of Brain Cancer
    • Early Cancer Detection
    • Research Initiatives
    • R&D Collaborations
    • Increase in Oncology Spending
    • Accelerated Approvals for Drugs Used in Rare Diseases
  • Market Restraints
    • Lack of Effective Treatment Options for Brain Tumors
    • High Cost
    • Low Screening
  • Current Market Trends
    • Immunotherapy
    • Combination Therapy
    • MRI-Guided Laser Surgery
    • Palliative Therapy
    • 3D Radiation Therapy
    • Precision Medicine and Companion Diagnostics
    • Polymer Wafer Implants
    • Tumor Treating Fields (TTF)

Chapter 5: Market Breakdown by Therapy

  • Introduction
  • Chemotherapy
    • Overview
    • Principle of Chemotherapy
    • BBB and Chemotherapy
    • Chemotherapeutic Agents
    • Side Effects of Chemotherapy
    • New Developments
    • Market Overview
    • Market Size and Forecast
  • Targeted Therapy
    • Introduction
    • Precision Medicine in Cancer
    • Types and Methods of Targeted Therapy
    • Drug Delivery Systems for Targeted Therapeutics
    • FDA-Approved Targeted Therapeutics
    • New Developments
    • Market Overview
    • Market Size and Forecast
  • Immunotherapy
    • Introduction
    • Immunotherapeutic Agents
    • New Developments
    • Market Overview

Chapter 6: Market Breakdown by Patient Age

  • Introduction
  • Overview
  • Treatment Options
  • Market Overview
  • Market Size and Forecast

Chapter 7: Market Breakdown by End User

Chapter 8: Market Breakdown by Region

  • Introduction
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 9: Emerging Technologies and Future Trends

  • Introduction
  • Cancer Vaccines
  • Nanomedicine
  • Stem Cell Therapy
  • Photodynamic Therapy
  • Focused Ultrasound Therapy
  • Radiomics and Pathomics
  • CRISPR
  • Artificial Intelligence
  • Advancements in Genomics and Personalized Medicine

Chapter 10: Clinical Research in Brain Tumor Therapeutics

  • Introduction
  • The Drug Development Process
    • Drug Discovery
    • Early Formulation Studies
    • Pre-Clinical Safety Studies
    • Clinical Trials
    • Regulatory Review
    • Post-Marketing Surveillance
  • Research Initiatives
    • Defeat GBM Research Collaborative
    • Cancer Moonshot
    • End Brain Cancer Initiative
    • Brain Cancer Translational Research Initiative
    • Pediatric Brain Tumor Initiative
    • GLIOTRAIN
    • GBM Agile
  • Clinical Trials and Experimental Treatments

Chapter 11: Patent Review

  • Introduction
  • Significant Patents

Chapter 12: Competitive Landscape and Market Strategies

  • Introduction
  • Major Players and Market Share Analysis
  • Market Strategies Employed, by Major Players
    • Research and Development
    • Patent Exclusivity
    • Mergers and Acquisitions (M&A)
  • New Developments
  • Porter's Analysis
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat from New Entrants
    • Threat from Substitutes
    • Market Competition

Chapter 13: Regulatory and Reimbursement Landscape

  • Introduction
  • Drug Development Regulations
    • U.S.
    • Canada
    • Mexico
    • Europe
    • Asia Pacific
    • ROW
  • Reimbursement Landscape

Chapter 14: Company Profiles

  • ASTRA ZENECA PLC
    • Business Overview
  • BRISTOL-MYERS SQUIBB CO.
    • Business Overview
    • Financial Information
    • Products and Services
    • Development and Strategies
  • CURTANA PHARMACEUTICALS, INC.
    • Business Overview
  • DEL MAR PHARMACEUTICALS, INC.
    • Business Overview
  • EISAI CO. LTD.
    • Business Overview
  • EMCURE PHARMA
    • Business Overview
  • F. HOFFMANN-LA ROCHE LTD.
    • Business Overview
    • Financial Information
    • Products and Services
    • Development and Strategies
    • Business Highlights
  • FRESENIUS KABI ONCOLOGY LTD.
    • Business Overview
  • IMMUNOCELLULAR THERAPEUTICS LTD.
    • Business Overview
  • ITEOS THERAPEUTICS
    • Business Overview
  • KAZIA THERAPEUTICS LTD.
    • Business Overview
  • MERCK & CO., INC.
    • Business Overview
    • Financial Information
    • Products and Services
    • Development and Strategies
    • Business Highlights
  • NAVINTA LLC
    • Business Overview
  • NEXTSOURCE BIOTECHNOLOGY LLC
    • Business Overview
    • Products and Services
    • Development and Strategies
    • Business Highlights
  • NORTHWEST BIOTHERAPEUTICS, INC.
    • Business Overview
  • NOVARTIS INTERNATIONAL AG
    • Business Overview
    • Financial Information
    • Products and Services
    • Development and Strategies
    • Business Highlights
  • TOCAGEN, INC.
    • Business Overview
  • UNITED THERAPEUTICS CORP.
    • Business Overview

Chapter 15: Appendix: Acronyms

Back to Top